GlassScriptPhysician profile
Justin Clay
NPI 1548669005
$7,092.86
in general payments reported to CMS, 2019-2025
36 companies · $679 in 2025
The $679 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $1,710 · 2023: $2,099 · 2024: $2,263 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,041.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,783.76 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $938.37 | 2021-2025 | |
| Lilly USA, LLC | $759.31 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $633.68 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $400.03 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $309.36 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $225.22 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.90 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.17 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $173.72 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $172.27 | 2023-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $134.55 | 2024 | |
| Novartis Pharmaceuticals Corporation | $97.05 | 2021-2023 | |
| Lundbeck LLC | $87.52 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $80.62 | 2023-2024 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $74.04 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $70.89 | 2021-2023 | Seglentis |
| Astellas Pharma US INC | $69.85 | 2021-2023 | Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.19 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $58.73 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $58.51 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $56.65 | 2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $53.03 | 2021-2022 | |
| Pfizer INC. | $50.17 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $41.78 | 2023 | Inpefa |
| Horizon Therapeutics Plc | $38.52 | 2023 | Krystexxa |
| Sunovion Pharmaceuticals INC. | $32.87 | 2022 | |
| Amarin Pharma, INC. | $32.57 | 2022 | |
| Amgen INC. | $31.44 | 2023-2024 | Repatha, Otezla |
| Abbott Laboratories | $30.78 | 2022-2024 | Freestyle Libre 3 |
| Scpharmaceuticals INC. | $25.10 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.50 | 2022 | |
| Esperion Therapeutics, INC. | $24.04 | 2024 | Nexletol |
| Abiomed | $19.58 | 2025 | |
| Davol INC. | $16.95 | 2025 | Progel Applicator Spray Tips |
| Cequr Corporation | $15.14 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.